Cramer's Mad Money - What To Do About Dell (1/15/13)

by: Miriam Metzinger

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday January 15.

What To Do About Dell (DELL)?

Dell (DELL) is a real no-man's land. At $13, risk and reward are about equal. It is likely that Dell will be taken private, but if no deal is made, the stock could work its way back to $11, because it doesn't have the earnings momentum to stay at $13. With a 6% decline in PCs, the industry is troubled, but Dell goes beyond PCs and offers solutions for small and mid-sized companies. Cramer would sell Dell if it goes to $14, but it could be a buy at around $10 or $11. Until then, Dell is not a stock to buy.

Regeneron Pharmaceuticals (NASDAQ:REGN), American Express (NYSE:AXP), Biogen IDEC (NASDAQ:BIIB), Facebook (NASDAQ:FB), Lennar (NYSE:LEN), Apple (NASDAQ:AAPL)

Right now, Cramer thinks the market is taking a pause that refreshes, although bears do not see it that way. Many are emphasizing the negatives, such as downgrades of Regeneron (REGN), American Express (AXP) and Biogen IDEC (BIIB) on fears of overvaluation and an alleged lack of catalysts for the companies. Cramer thinks Facebook (FB) could be hit with a downgrade, as well as Lennar (LEN), even though it reported a strong quarter. While the apparent decline in demand for Apple's (AAPL) iPhones is disconcerting, and the wrangling in Washington over the debt is not inspiring, Cramer thinks the current lackluster action is just a breather for the market, and not a long-term decline. He mentioned 6 similar scenarios since 2000 when the market took a break after a bull run, but the critics thought a bull market was ahead. In this case, as in those examples, Cramer thinks the critics are wrong.

Which to Buy: Abbott Labs (NYSE:ABT) or AbbVie (NYSE:ABBV)? Other stock mentioned: Gilead (NASDAQ:GILD)

Cramer applauded Abbott Labs' (ABT) move to spin off its slower growth pharma division into a separate company, AbbVie (ABBV). Now Abbott Labs is a faster growing company, with a large nutritional segment that should grow by 35%, a medical devices unit and a diagnostics business that should benefit from the need to cut healthcare costs. Cramer got behind ABT on the announcement of the break-up in 2011, and the stock has risen 24% since. ABT has one of the largest exposures to emerging markets of any healthcare company, 40%, while the industry average is 10-20%. While AbbVie offers a generous 4.7% yield, it has little in the pipeline, and its main drug for rheumatoid arthritis is facing a patent cliff in the next few years, with uncertainty on how it will be replaced. While AbbVie has a treatment for Hepatitis C, Gilead (GILD) is still the dominant player in the Hepatitis C space. Cramer would buy ABT because of its strong growth prospects and its margin expansion; it now trades at a multiple of 17 with growth in the low teens.

CEO Interview: Randy Foutch, Laredo Petroleum Holdings (NYSE:LPI)

Laredo Energy (LPI) had its IPO recently, and is an oil and gas stock with significant assets in the Permian Basin and other shales. The company expects to grow its oil production by 25%. While there are concerns about the company's ability to raise money for drilling projects, CEO Randy Foutch says LPI has access to public equity. The company is increasing its exposure to oil, since Foutch says he does not see natural gas prices rising dramatically in the near future. Cramer suggested this stock for investors who believe oil will stay strong.


Jim Cramer's Action Alerts PLUS: Trade right alongside a Wall Street pro! Start your 14-day FREE trial today.

Get Cramer's Picks by email - it's free and takes only a few seconds to sign up.